Since the B-RAF inhibitor Dabrafenib has recently been reported to inhibit RIP3 by its adenosine-5′-triphosphate (ATP)-competitive binding to the enzyme [19], we also tested the effect of Dabrafenib on the induction of necroptosis in AML cells. The gene discussed is BRAF; the disease is acute myeloid leukemia.